International Carbapenems Study Group |
|
|
|
|
|
|
New cases# |
30/140 21.4% (14.6–28.2) |
|
90/140 64.3% (56.4–72.2) |
81/130 62.3% (53.9–70.6) |
60/137 43.8% (35.5–52.1) |
19/84 22.6% (13.7–31.5) |
Previously-treated tuberculosis cases |
107/195 54.9% (47.9–61.9) |
|
140/197 71.1% (64.8–77.4) |
113/169 66.9% (59.8–74.0) |
113/176 64.2% (57.1–71.3) |
80/140 57.1% (48.9–65.3) |
All cases |
137/336 40.8% (35.6–46.1) |
|
232/339 68.4% (63.5–73.4) |
195/300 65.0% (59.6–70.4) |
174/314 55.4% (49.9–60.9) |
100/225 44.4% (37.9–50.9) |
Stratification by geographical region |
|
|
|
|
|
|
International Carbapenems Study Group Europe |
|
|
|
|
|
|
Previously-treated tuberculosis cases |
61/142 43.0% (34.9–51.1) |
|
103/142 72.5% (65.2–79.8) |
83/124 66.9% (58.6–75.2) |
89/141 63.1% (55.1–71.1) |
44/87 50.6% (40.1–61.1) |
All cases |
91/283 32.2% (26.8–37.6) |
|
195/284 68.7% (63.3–74.1) |
165/255 64.7% (58.8–70.6) |
150/279 53.8% (48.0–59.7) |
64/172 37.2% (30.0–44.4) |
International Carbapenems Study Group South America |
|
|
|
|
|
|
Previously-treated tuberculosis cases |
46/53 86.8% (77.7–95.9) |
|
37/55 67.3% (54.9–79.7) |
30/45 66.7% (52.9–80.5) |
24/35 68.6% (53.2–84.0) |
36/53 67.9% (55.3–80.5) |
All cases |
46/53 86.8% (77.7–95.9) |
|
37/55 67.3% (54.9–79.7) |
30/45 66.7% (52.9–80.5) |
24/35 68.6% (53.2–84.0) |
36/53 67.9% (55.3–80.5) |
Control |
|
|
|
|
|
|
International Carbapenems Study Group control group |
|
|
|
|
|
|
New cases (108/168) |
15/105 14.3% (7.6–21.0) |
|
61/105 58.1% (48.7–67.5) |
53/96 55.2% (45.3–65.1) |
35/103 34.0% (24.9–43.1) |
7/56 12.5% (3.8–21.2) |
Previously-treated tuberculosis cases (59/168) |
12/56 21.4% (10.7–32.1) |
|
30/58 51.7% (38.9–64.6) |
20/45 44.4% (29.9–58.9) |
28/56 50.0% (36.9–63.1) |
9/32 28.1% (12.5 - -43.7) |
All cases |
27/161 16.8% (11.0–22.6) |
|
92/164 56.1% (48.5–63.7) |
73/141 51.8% (43.6–60.0) |
63/159 39.6% (32.0–47.2) |
16/88 18.2% (10.1–26.3) |